OBJECTIVE. The atherosclerosis is the most common cause of death and disability in developed countries by causing ischemic cardiopathic and stroke. The ischemic atherotrombotic stroke is the most frequent form of the last one. In this sense we review herein the mechanisms underlying the artherosclerotic process. DEVELOPMENT. It is understood as an inflammatory disease, by taking into account the widely accepted hypothesis by Ross: it was firstly stated in structural terms, as macrophages and T/B linfocities were present in the arterial wall from the first stages of the disease (fatty streak) to the last and complicated ones. The starting point is a functional endothelial damage, secondary to mechanical or vascular risk factors and called ‘response-to-injury hypothesis’. The next step is an inflammatory cascade that involves humoral (citokines, growth factors) and cellular (increased quimiotaxis, adherece and infiltration of inflamatory cells) mechanisms. They interact among them, outbalanced and in a progresssive way that leads to the final fibroproliferative response. Every stage has his own inflammatory components and interactive pathways. The following elements are outstanding in this process: 1) Adhesion molecules, including E-selectin, ICAM-1 and VCAM-1, that are increased locally in the plaques and as circulating elements; plaquetary receptors of the type IIb/IIIa are integrins wich belong to the same family; 2) Citokines with either proinflammatory activity-like IL-1, the TNF-a and linfocitary ligands like the CD-40, or with antiinflammatory activity like the gamma interpheron; 3) Growth factors, with plaquetary (PDGF) and fibroblastic (FGF) variants as the cornerstone; 4) Markers of systemic inflammation, overall plasma C reactive protein and fibrinogen, that predict the risk of stroke and cardiovascular death; IL-6, complement, thrombin and heat-shock proteins (HSP) would act in a similar but less conclusive way.
CONCLUSIONS The evidences of the pivotal role of the inflammation in the stroke allow to develop therapeutical strategies to prevent the disease: fostering natural antiinflamatory mechanisms, or inhibiting inflammatory elements by selective (monoclonal antibodies) or non-selective (IIb/IIIa receptors, antiinflammatory drugs) pathways are distinctily glimpsed, ongoing or fully developed.
KeywordsAntiinflammatory mechanismsAtherosclerosisInflammationIschaemic strokeCategoriesPatología vascularTécnicas exploratorias
FULL TEXT(solo disponible en lengua castellana / Only available in Spanish)
Si ya es un usuario registrado en Neurologia, introduzca sus datos de inicio de sesión.
Rellene los campos para registrarse en Neurologia.com y acceder a todos nuestros artículos de forma gratuita
¿Olvidó su contraseña? Introduzca su correo electrónico y le haremos llegar una nueva
¡CONVIÉRTASE EN USUARIO PREMIUM DE NEUROLOGIA.COM!
Al hacerse premium, está apoyándonos para que Revista de Neurología
siga siendo uno de los referentes de habla hispana en la difusión del
conocimiento en neurociencias. ¡Gratuita tanto para autores como para
todos los usuarios de la web!
Además, por convertirte en usuario premium, recibirá las siguientes ventajas:
Plaza asegurada en todos nuestros Másteres (www.ineurocampus.com)
Descuento del 5% en los cursos de “Actualización en Neurología”, la FMC que estará disponible próximamente en la web.
Descarga gratuita en formato PDF dos de las obras con más éxito publicadas por Viguera Editores:
Oromotors Disorders in childhood (M. Roig-Quilis; L. Pennington)
Manual de Neuropsicología 2ª ed. (J. Tirapu-Ustárroz; M. Ríos-Lago; F. Maestú)
El precio para hacerse Premium durante el periodo de un año es de 5€, que podrá pagar a continuación a través de una pasarela de pago seguro con tarjeta de crédito, transferencia bancaria o PayPal:
OPEN ACCESS
